Company intelligence / Profile preview
Panacela Labs
New York, United Statespanacelalabs.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Panacela Labs has completed a Phase I clinical trial with its lead candidate Mobilan, an immunotherapy targeting TLR5 for non-metastatic prostate cancer. The study demonstrated safety, pharmacokinetics, and pharmacodynamics. Another key asset, Xenomycins—a novel antimicrobial—has shown promising preclinical efficacy against fungal pathogens such as Candida and Aspergillus.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesImmunotherapeuticsPossibly others in preclinical development
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Roswell Park Cancer InstituteChildren’s Cancer Institute AustraliaCleveland Clinic FoundationRUSNANO investment partnership
Beyond the preview
Go deeper on Panacela Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panacela Labs.